Atea Pharmaceuticals completes enrolment in Phase 3 C-FORWARD HCV trial
Atea Pharmaceuticals has completed patient enrolment in C-FORWARD, its Phase 3 hepatitis C virus (HCV) trial conducted outside North America, bringing the company a step closer to a potential regulatory submission for its fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR).
More than 880 treatment-naïve patients were enrolled across approximately 120 clinical sites in 17 countries. The trial is comparing BEM/RZR against sofosbuvir and velpatasvir, a standard-of-care regimen marketed by Gilead Sciences. Topline results are expected around the end of 2026. Meanwhile, the parallel North American trial, C-BEYOND, is tracking toward a mid-year 2026 readout, which the company confirmed remains on schedule.
Trial design and drug profile
C-FORWARD is a randomised, open-label study in which BEM/RZR is administered once daily for eight weeks in patients without cirrhosis and 12 weeks in those with compensated cirrhosis. The comparator arm receives sofosbuvir/velpatasvir for 12 weeks regardless of cirrhosis status. The primary endpoint is HCV RNA below the lower limit of quantitation at 24 weeks from treatment start, encompassing sustained virologic response 12 weeks post-treatment (SVR12).
The enrolled population spans a broad range of HCV genotypes, including those more prevalent outside North America. That diversity is significant: a broad-genotype label would support commercial uptake across markets where genotype 3 and genotype 6 infections are common, particularly in South and Southeast Asia.
Bemnifosbuvir is a nucleotide analogue polymerase inhibitor that Atea says has demonstrated roughly tenfold greater in vitro potency against HCV genotypes 1 through 5 compared with sofosbuvir, including activity against the S282T resistance substitution. Ruzasvir, an NS5A inhibitor, has shown pan-genotypic activity in picomolar ranges in preclinical models. Both compounds have been administered to more than 2,800 patients in prior studies. Jean-Pierre Sommadossi, founder and chief executive of Atea, said the regimen's profile, combining short treatment duration, a low drug-drug interaction risk and no food-effect requirement, is "intended to uniquely position" the company to address HCV at a global scale, with an ultimate aim of contributing to eradication of the disease.
Market context and competitive landscape
HCV drug development is a space with a formidable incumbent. Gilead's Epclusa (sofosbuvir/velpatasvir) and Harvoni franchises have set a high cure-rate bar, routinely achieving SVR12 rates above 95% in clinical trials. AbbVie's Maviret (glecaprevir/pibrentasvir) has further compressed treatment duration in many patient subgroups. For BEM/RZR to carve out meaningful share, Atea will need to demonstrate non-inferiority or superiority in SVR12, while making a credible case on convenience and tolerability.
The global burden of disease remains substantial. An estimated 50 million people worldwide live with chronic HCV infection, and around one million new infections are recorded each year. In the United States, new diagnoses continue to outpace annual cure rates, driven in part by injection-drug-use transmission in younger adults. That treatment gap represents a genuine commercial and public health opportunity, particularly if Atea can demonstrate strong performance in patient populations that are harder to engage with existing regimens.
C-FORWARD and C-BEYOND together constitute what Atea describes as the first global Phase 3 programme to run head-to-head trials of direct-acting antivirals for HCV. If both readouts are positive, the dataset would position the company for regulatory submissions in both the US and international markets through 2027. The anticipated mid-2026 C-BEYOND readout is the nearer catalyst for investors to watch.